Updated on: 2026-05-08
Table of Contents
🧮 Cost-per-dose math
The free GLP1 Calculator's reconstitution math helps determine cost-per-mg and cost-per-dose for vial-format compounded products.
- Retail pricing without insurance
- Commercial insurance coverage landscape
- Medicare coverage
- Medicaid coverage
- Manufacturer savings cards
- Direct-to-consumer pricing (LillyDirect, NovoCare)
- Compounded GLP-1 pricing
- International pharmacy pricing
- Total annual cost reference
- FAQ
- Disclaimer
1) Retail pricing without insurance
Documented retail pricing in 2026 (without insurance, paying cash at chain pharmacy):
- Ozempic® — $1,000–$1,400 per month (one pen covering 4 weekly doses).
- Wegovy® — $1,300–$1,600 per month (4 single-use pens).
- Mounjaro® — $1,000–$1,200 per month (4 single-use pens).
- Zepbound® (pen) — $1,000–$1,300 per month (4 single-use pens).
- Zepbound® (vial via LillyDirect) — $349–$499 per month (4 single-dose vials + syringes).
- Rybelsus® (oral semaglutide) — $900–$1,200 per month (30 daily tablets).
Pricing varies by pharmacy, dose strength, and geographic region. GoodRx and similar pharmacy-coupon services document modest discounts on retail prices — typically 5–15% off the cash price.
2) Commercial insurance coverage landscape
Documented commercial insurance coverage:
- Type 2 diabetes indication — documented as covered by most commercial insurance plans for Ozempic and Mounjaro. Out-of-pocket cost typically $25–$200 per month with copay.
- Weight management indication — documented as inconsistently covered. Many commercial plans exclude weight-management medications via formulary or specific obesity-medication exclusion. When covered, prior authorization typically required (often requiring documentation of BMI, comorbidities, and prior weight-loss attempts).
- Cardiovascular indication (Wegovy 2024) — coverage is improving as plans update formularies. Documented practice is checking the specific plan formulary for Wegovy CV indication coverage.
- Sleep apnea indication (Zepbound 2024) — documented as variably covered following the 2024 approval.
- Plan-specific caps — some plans cap GLP-1 coverage at a certain duration or total cost; others apply step therapy (requiring metformin or other diabetes medications first).
3) Medicare coverage
Documented Medicare coverage:
- Medicare Part D — covers Ozempic, Mounjaro, and Rybelsus for type 2 diabetes diagnosis. Cost-sharing varies by plan; donut hole / catastrophic coverage applies.
- Wegovy — Medicare statutorily excludes weight-loss medications. The 2024 cardiovascular indication for Wegovy began Medicare coverage for that specific indication.
- Zepbound — same statutory exclusion for weight management. The 2024 sleep apnea indication may shift coverage.
- Medicare Part B — does not cover oral or self-injected GLP-1s; only covers physician-administered medications.
4) Medicaid coverage
Documented Medicaid coverage:
- State-by-state variation — Medicaid coverage of GLP-1s is documented as varying by state. Most states cover Ozempic and Mounjaro for diabetes; weight-management coverage (Wegovy, Zepbound) is more variable.
- Prior authorization — documented as standard for GLP-1 coverage in most state Medicaid programs.
5) Manufacturer savings cards
Documented manufacturer programs:
- Novo Nordisk Ozempic Savings Offer — for commercially-insured patients, documented as reducing out-of-pocket cost; ineligible for Medicare/Medicaid patients.
- Novo Nordisk Wegovy Savings Offer — for commercially-insured patients with Wegovy coverage; documents specific monthly caps. Ineligible for government insurance.
- Eli Lilly Mounjaro Savings Card — for commercially-insured diabetes patients; documents reduction to $25 per month with eligible coverage.
- Eli Lilly Zepbound Savings Card — for commercially-insured patients with Zepbound coverage; documents specific monthly caps.
Documented eligibility requirements for all manufacturer cards include U.S. residency, commercial insurance (not Medicare/Medicaid/VA/DOD), and prescriber-issued prescription. Cards are typically not stackable with other discount programs.
6) Direct-to-consumer pricing (LillyDirect, NovoCare)
Documented direct-to-consumer pharmacy programs:
- LillyDirect — Eli Lilly's direct-to-consumer pharmacy. Documents Zepbound vial pricing of $349–$499 per month (4 vials, dose-dependent), no insurance required. Pen format also available at retail-comparable pricing.
- NovoCare — Novo Nordisk's patient support program. Documents savings programs, patient assistance for low-income patients, and educational resources. Direct-to-consumer pricing for Wegovy/Ozempic is more limited than LillyDirect's Zepbound vial program.
7) Compounded GLP-1 pricing
Documented compounded GLP-1 pricing:
- Compounded semaglutide — historically $200–$500 per month through 503A pharmacies; subscription telehealth services (Hers, Ro, Calibrate, Sequence, etc.) documented similar pricing. The FDA's 2024 removal of semaglutide from the shortage list reduced widespread compounding; some pharmacies continue under specific patient-specific compounding criteria.
- Compounded tirzepatide — $200–$500 per month through 503A pharmacies. Tirzepatide remains on the FDA shortage list at certain doses, supporting continued compounding.
- Telehealth platform pricing — subscription services bundle the medication with provider consultation. Documented all-in pricing typically $250–$450 per month.
8) International pharmacy pricing
Documented international pricing:
- Mexico — Ozempic retail roughly $200–$400 per month at Mexican pharmacies. Cash-pay model. See our Mexico pharmacy reference.
- Canada — Ozempic retail roughly $300–$500 per month at Canadian pharmacies. Documented as requiring valid Canadian or U.S. prescription for purchase.
- Europe (UK, Germany, France, Spain) — Ozempic retail roughly $100–$300 per month at NHS or equivalent. Price reflects national health system negotiated rates, not free market.
- India — Ozempic retail roughly $100–$200 per month at Indian pharmacies (where available).
Personal-import for medication purposes is governed by FDA personal-import policy; documented practice references 90-day supply limit and prescription documentation. The FDA's "personal import" policy is enforcement discretion, not affirmative legal authorization.
9) Total annual cost reference
Documented annualized cost ranges (12 months):
| Scenario | Annual cost (USD) |
|---|---|
| Ozempic with commercial insurance + savings card | $300–$1,200 |
| Wegovy with commercial insurance + savings card | $300–$2,400 |
| Mounjaro with commercial insurance + savings card | $300–$1,200 |
| Zepbound with commercial insurance + savings card | $300–$2,400 |
| Zepbound vial via LillyDirect (cash, no insurance) | $4,200–$5,988 |
| Branded pen retail (cash, no insurance) | $12,000–$19,200 |
| Compounded GLP-1 via 503A pharmacy | $2,400–$6,000 |
| Telehealth platform with compounded GLP-1 | $3,000–$5,400 |
| Mexican pharmacy (cash, in-person) | $2,400–$4,800 |
| Canadian pharmacy (cross-border) | $3,600–$6,000 |
The cost spread between scenarios documents why GLP-1 cost is one of the most-asked patient questions.
10) FAQ
Why are GLP-1 medications so expensive in the U.S.?
Documented factors include: high R&D and FDA-approval costs, manufacturer pricing strategy, insurance coverage variability for weight-management indications, and the absence of generic competition (semaglutide and tirzepatide remain patent-protected through the late 2020s and beyond).
What's the cheapest legitimate GLP-1 option?
Documented lowest-cost options for U.S. patients:
- Insurance + manufacturer savings card — $25–$200/month for eligible patients
- Zepbound vial via LillyDirect — $349–$499/month with no insurance
- Compounded GLP-1 via 503A pharmacy — $200–$500/month (where legally available)
- Mexican pharmacy in-person purchase — $200–$400/month (with travel cost added)
Does Medicare cover Ozempic for weight loss?
Medicare does not cover Ozempic specifically for weight loss. Medicare Part D covers Ozempic for type 2 diabetes. Medicare statutorily excludes weight-loss medications from coverage; the 2024 Wegovy cardiovascular indication began limited coverage for that specific use case.
Are compounded GLP-1s still legal?
Compounded GLP-1s are subject to evolving FDA regulations. Compounding under 503A or 503B regulations is legal under specific conditions (drug shortage, patient-specific compounding). Documented 2026 status: tirzepatide remains on the FDA shortage list at certain doses (supporting compounding); semaglutide is largely off the shortage list (limiting compounding). The legal landscape continues to evolve.
Can I buy GLP-1 in Mexico for personal use?
Documented practice references purchasing Ozempic at Mexican pharmacies for personal use. U.S. CBP enforcement discretion permits 90-day supply with original packaging and prescription documentation. The FDA's personal-import policy is enforcement discretion, not affirmative legal authorization. See our Mexico pharmacy reference for details.
Trademark notice: Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. LillyDirect™ is a service of Eli Lilly. NovoCare® is a service of Novo Nordisk. Vialcase is independent and is not affiliated with any pharmaceutical manufacturer or pharmacy program. Pricing references are descriptive of publicly available information at time of writing and are subject to change.
Recommended Travel Cases
Vialcase produces hard-shell vial cases sized for GLP-1 pens, peptide vials, BAC water bottles, and reconstitution supplies. Three options most commonly referenced for travel:
Browse all vial storage cases →
Disclaimer
This article is informational reference only on documented GLP-1 pricing landscape. It is not financial, medical, or legal advice. Pricing changes frequently; verify current pricing directly with pharmacies and manufacturer programs. Refer to a licensed healthcare provider for clinical guidance and to an insurance/financial professional for specific cost-coverage questions.
